The FDA has committed to working with other agencies, health care providers, industry, and patients and families to deal proactively with the opioid abuse crisis, while safeguarding appropriate access to vitally important pain medications for the patients who need them.
No takes yet. Share an insight, caveat, or question.
Califf et al. (2016) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: